Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
| ▸ | ADH4 | P08319 | 1/20 | 0.30 |
| ▸ | ADH7 | P40394 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16917410 | 0.69 | TP53 (0.41) | TP53FAAHADH1BADH1CADH1A | |
| SCHEMBL24667475 | 0.69 | TP53 (0.41) | TP53FAAHADH1BADH1CADH1A | |
| SCHEMBL24665644 | 0.69 | TP53 (0.41) | TP53FAAHADH1BADH1CADH1A | |
| SCHEMBL12656353 | 0.68 | TP53 (0.39) | TP53ADH1BADH1CADH1AADH4 | |
| SCHEMBL11335725 | 0.67 | TP53 (0.42) | TP53FAAHADH1BADH1CADH1A | |
| SCHEMBL12656354 | 0.66 | TP53 (0.38) | TP53FAAHADH1BADH1CADH1A | |
| SCHEMBL1085797 | 0.66 | ZDHHC7 (0.36) | TP53ADH1BADH1CADH1AADH4 | |
| SCHEMBL15632534 | 0.65 | TP53 (0.41) | TP53ADH1BADH1CADH1AADH4 | |
| SCHEMBL9290259 | 0.65 | NPSR1 (0.30) | — | |
| SCHEMBL25519813 | 0.64 | EPHX1 (0.55) | TP53FAAHADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | TP53 346/4885SLC6A4 4134/4885SLC6A3 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.